Tags : Cardiovascular Safety

AstraZeneca Reports Results of Roxadustat in Global Phase III Programme

Shots: The P-III global programme involves assessing of Roxadustat vs PBO & epoetin alfa in 9,000+ patients with anemia + CKD not on dialysis (NDD) , dialysis-dependent (DD), ID respectively Pooled analyses results: MACE/MACE+ in NDD & DD patients, clinically no difference; MACE/MACE+ in ID patients shows better results Roxadustat is hypoxia-inducible-factor prolyl hydroxylase inhibitor, […]Read More